Diluted HEPS decreased to 620.7cps (-6.0% y-y). Normalised Diluted HEPS increased to 688.3cps (+1.3% y-y).
Turnover increased by 10.4% y-y, driven by strong growth in commercial pharmaceutical regions such as the Americas (+27.3% y-y), AME (+7.2% y-y) and Australasia (+5.1% y-y).
Group GPM down 280bps to 44.0%.
Total expenses up 15.4% y-y, with expenses to sales increasing to 28.5% (1H23: 27.3%).
OPM down by 370bps to 16.6%. This was due to elevated transaction costs related to acquisitions, as well as increased intangible asset impairments due to the VBP impact in China.
No dividend (1H23: nil).
Gross debt increased significantly to R32.1bn (1H23: R24.1bn).
The acquisition of the product portfolio from Viatris for Latin America, amounting to R5.3bn, was fully funded and paid for in 1H24.
